A newly published case report describes successful treatment of new-onset plaque psoriasis with secukinumab in a patient on peritoneal dialysis, an outcome the authors documented in Frontiers.

The report adds to a narrow evidence base on biologic therapy in dialysis-dependent psoriasis patients, a population largely excluded from pivotal secukinumab trials.

What did the case report document?

According to the case report's title, the clinicians achieved clearance of new-onset plaque psoriasis with secukinumab in a patient receiving peritoneal dialysis. The authors frame the outcome as successful, signaling tolerability and skin clearance in a patient where systemic drug clearance is altered by renal replacement therapy.

Why does the dialysis context matter?

• Standard secukinumab dosing derives from trials in patients with normal to moderately impaired renal function.
• Peritoneal dialysis changes drug pharmacokinetics and limits enteral options after dosing.
• Guidelines offer limited direction on IL-17 inhibitors in this group.

The case therefore addresses a recurring clinical gap: which biologic to start when a psoriasis patient reaches end-stage renal disease.

What does the source confirm and not confirm?

The available source material confirms the title claim of successful treatment and the publication venue (Frontiers). It does not detail baseline PASI, time to clearance, the dosing regimen used, adverse events, or follow-up duration. Readers seeking those parameters should consult the full Frontiers case report directly.

What is the regulatory standing of secukinumab?

Secukinumab, a fully human anti–IL-17A monoclonal antibody, holds approvals for moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Its label does not currently include specific dosing guidance for patients on peritoneal dialysis, making case-level evidence clinically relevant.

Further accumulation of dialysis-population data will determine whether guideline language for IL-17 inhibitors needs adjustment.